We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
+19.43%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$151M
AUM Growth
+$3.58M
Cap. Flow
-$9.16M
Cap. Flow %
-6.07%
Top 10 Hldgs %
95.41%
Holding
16
New
3
Increased
6
Reduced
2
Closed
2
Avg Time Held
1.5 quarters
Top 10 Avg Time Held
1.7 quarters
Top 20 Avg Time Held
1.5 quarters

Top Buys

Rank Stock Value
1
ESPR icon
Esperion Therapeutics
ESPR
+$4.88M
2
DVAX icon
Dynavax Technologies
DVAX
+$4.48M
3
XLRN
Acceleron Pharma
XLRN
+$2.9M
4
CMRX icon
Chimerix, Inc.
CMRX
+$2.77M
5
DERM icon
Dermira, Inc.
DERM
+$2.03M

Top Sells

Rank Stock Value
1
RLYP
RELYPSA INC COM
RLYP
+$20.6M
2
CALA
Calithera Biosciences, Inc
CALA
+$4.87M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$2.38M
4
SAGE icon
Sage Therapeutics
SAGE
+$2.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.15%
2 Miscellaneous 4.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALDR
1
DELISTED
Alder Biopharmaceuticals
ALDR
$34.8M 23.09%
657,783
+24,490
+4% +$891K
2014 Q4
2 quarters
ARAV
2
DELISTED
Aravive, Inc. Common Stock
ARAV
$31M 20.57%
339,871
– –
2014 Q4
2 quarters
OXFD
3
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$19.1M 12.64%
1,377,497
– –
2014 Q4
2 quarters
CMRX icon
4
DELISTED
Chimerix, Inc.
CMRX
$14.8M 9.82%
320,608
+69,000
+27% +$2.77M
2014 Q4
2 quarters
DVAX icon
5
DELISTED
Dynavax Technologies
DVAX
$14.3M 9.51%
612,498
+205,505
+50% +$4.48M
2014 Q4
2 quarters
MRNS icon
6
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$7.58M 5.02%
163,374
+32,311
+25% +$1.21M
2014 Q4
2 quarters
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$3.41B
$7.42M 4.92%
177,230
+44,169
+33% +$1.71M
2014 Q4
2 quarters
RLYP
8
DELISTED
RELYPSA INC COM
RLYP
$7.32M 4.85%
221,204
-598,629
-73% -$20.6M
2014 Q4
2 quarters
ESPR icon
9
DELISTED
Esperion Therapeutics
ESPR
$4.07M 2.7%
+49,816
New +$4.88M
2015 Q2
0 quarters
KPTI icon
10
Karyopharm Therapeutics
KPTI
$13.7M
$3.45M 2.28%
8,446
– –
2014 Q4
2 quarters
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$2.84M 1.88%
+89,738
New +$2.9M
2015 Q2
0 quarters
DERM icon
12
DELISTED
Dermira, Inc.
DERM
$2.31M 1.53%
+131,590
New +$2.03M
2015 Q2
0 quarters
CALA
13
DELISTED
Calithera Biosciences, Inc
CALA
$970K 0.64%
6,795
-21,007
-76% -$4.87M
2014 Q4
2 quarters
AKAO
14
DELISTED
Achaogen Inc
AKAO
$800K 0.53%
132,728
+4,000
+3% +$24.8K
2015 Q1
1 quarter
SAGE icon
15
DELISTED
Sage Therapeutics
SAGE
– –
-43,770
Closed -$2.2M –
GEVA
16
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-24,379
Closed -$2.38M –

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q2 2015 Portfolio in Review

As of Q2 2015, New Leaf Venture Partners held 16 positions worth $151M, up 2.4% from $147M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

New Leaf Venture Partners withdrew a net $9.16M in Q2 2015, closing 2 positions and reducing 2 holdings. Its most notable exit was SYNAGEVA BIOPHARMA CORP COM STK (DE), an estimated $2.38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 78% a quarter earlier, followed by Miscellaneous.

Against the trend, New Leaf Venture Partners opened a new position in Esperion Therapeutics worth $4.07M.

  • New Leaf Venture Partners's largest Q2 2015 buy was Esperion Therapeutics: 49,816 shares worth $4.07M.
  • New Leaf Venture Partners added most to Dynavax Technologies in Q2 2015, an estimated $4.48M increase.
  • New Leaf Venture Partners's biggest Q2 2015 reduction was RELYPSA INC COM, cutting an estimated $20.6M.
  • New Leaf Venture Partners fully exited SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2015, selling an estimated $2.38M.
  • New Leaf Venture Partners's ten largest holdings make up 95% of its $151M portfolio in Q2 2015.
  • New Leaf Venture Partners opened 3 new positions and closed 2 in Q2 2015.
  • New Leaf Venture Partners's portfolio value rose 2.4% quarter-over-quarter to $151M.

Based on New Leaf Venture Partners's 13F filing for Q2 2015, filed 14 Aug 2015.